27,000 patient PCSK9 inhibitor trial meets main endpoints

Amgen announced on Thursday afternoon that the FOURIER trial had met both its primary composite endpoint (cardiovascular death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the even more rigorous key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke). The company also announced that an important FOURIER substudy, the ...

Already a member?

Login to keep reading.

© 2021 the limbic